FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2616585988> ?p ?o ?g. }

• W2616585988 abstract "Quality of artemisinin-based combination therapy (ACT) is important for ensuring malaria parasite clearance and protecting the efficacy of artemisinin-based therapies. The extent to which non quality-assured ACT (non-QAACT), or those not granted global regulatory approval, are available and used to treat malaria in endemic countries is poorly documented. This paper uses national and sub-national medicine outlet surveys conducted in eight study countries (Benin, Kinshasa and Kantanga [Democratic Republic of the Congo, DRC], Kenya, Madagascar, Nigeria, Tanzania, Uganda and Zambia) between 2009 and 2015 to describe the non-QAACT market and to document trends in availability and distribution of non-QAACT in the public and private sector. In 2014/15, non-QAACT were most commonly available in Kinshasa (83%), followed by Katanga (53%), Nigeria (48%), Kenya (42%), and Uganda (33%). Non-QAACT accounted for 20% of the market share in the private sector in Kenya, followed by Benin and Uganda (19%), Nigeria (12%) and Zambia (8%); this figure was 27% in Katanga and 40% in Kinshasa. Public sector non-QAACT availability and distribution was much lower, with the exception of Zambia (availability, 85%; market share, 32%). Diverse generics and formulations were available, but non-QAACT were most commonly artemether–lumefantrine (AL) or dihydroartemisinin-piperaquine (DHA PPQ), in tablet formulation, imported, and distributed in urban areas at either pharmacies or drug stores. The number of unique manufacturers supplying non-QAACT to each country ranged from 9 in Uganda to 92 in Nigeria. Addressing the availability and distribution of non-QAACT will require effective private sector engagement and evidence-based strategies to address provider and consumer demand for these products. Given the variation in non-QAACT markets observed across the eight study countries, active efforts to limit registration, importation and distribution of non-QAACT must be tailored to the country context, and will involve addressing complex and challenging aspects of medicine registration, private sector pharmaceutical regulation, local manufacturing and drug importation. These efforts may be critical not only to patient health and safety, but also to effective malaria control and protection of artemisinin drug efficacy in the face of spreading resistance." @default.
• W2616585988 created "2017-05-26" @default.
• W2616585988 creator A5013453998 @default.
• W2616585988 creator A5014597322 @default.
• W2616585988 creator A5026823453 @default.
• W2616585988 date "2017-05-25" @default.
• W2616585988 modified "2023-10-13" @default.
• W2616585988 title "Do anti-malarials in Africa meet quality standards? The market penetration of non quality-assured artemisinin combination therapy in eight African countries" @default.
• W2616585988 cites W1510743507 @default.
• W2616585988 cites W1668247097 @default.
• W2616585988 cites W1823677338 @default.
• W2616585988 cites W1900905299 @default.
• W2616585988 cites W1964621550 @default.
• W2616585988 cites W1976640042 @default.
• W2616585988 cites W2004987422 @default.
• W2616585988 cites W2020445101 @default.
• W2616585988 cites W2068129931 @default.
• W2616585988 cites W2082413458 @default.
• W2616585988 cites W2089905442 @default.
• W2616585988 cites W2096595824 @default.
• W2616585988 cites W2112910792 @default.
• W2616585988 cites W2122992752 @default.
• W2616585988 cites W2133825501 @default.
• W2616585988 cites W2135267657 @default.
• W2616585988 cites W2138525153 @default.
• W2616585988 cites W2144493718 @default.
• W2616585988 cites W2148971244 @default.
• W2616585988 cites W2152222678 @default.
• W2616585988 cites W2157319031 @default.
• W2616585988 cites W2158111301 @default.
• W2616585988 cites W2161032381 @default.
• W2616585988 cites W2161311583 @default.
• W2616585988 cites W2164318124 @default.
• W2616585988 cites W2165308642 @default.
• W2616585988 cites W2165402727 @default.
• W2616585988 cites W2171031967 @default.
• W2616585988 cites W2171102256 @default.
• W2616585988 cites W2171439211 @default.
• W2616585988 cites W2345438034 @default.
• W2616585988 cites W2415846806 @default.
• W2616585988 cites W275778308 @default.
• W2616585988 cites W4233884895 @default.
• W2616585988 doi "https://doi.org/10.1186/s12936-017-1818-8" @default.
• W2616585988 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5444102" @default.
• W2616585988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28539125" @default.
• W2616585988 hasPublicationYear "2017" @default.
• W2616585988 type Work @default.
• W2616585988 sameAs 2616585988 @default.
• W2616585988 citedByCount "20" @default.
• W2616585988 countsByYear W26165859882017 @default.
• W2616585988 countsByYear W26165859882018 @default.
• W2616585988 countsByYear W26165859882019 @default.
• W2616585988 countsByYear W26165859882020 @default.
• W2616585988 countsByYear W26165859882021 @default.
• W2616585988 countsByYear W26165859882022 @default.
• W2616585988 countsByYear W26165859882023 @default.
• W2616585988 crossrefType "journal-article" @default.
• W2616585988 hasAuthorship W2616585988A5013453998 @default.
• W2616585988 hasAuthorship W2616585988A5014597322 @default.
• W2616585988 hasAuthorship W2616585988A5026823453 @default.
• W2616585988 hasBestOaLocation W26165859881 @default.
• W2616585988 hasConcept C110121322 @default.
• W2616585988 hasConcept C121426985 @default.
• W2616585988 hasConcept C134306372 @default.
• W2616585988 hasConcept C136264566 @default.
• W2616585988 hasConcept C144133560 @default.
• W2616585988 hasConcept C147859227 @default.
• W2616585988 hasConcept C162324750 @default.
• W2616585988 hasConcept C203014093 @default.
• W2616585988 hasConcept C2776120307 @default.
• W2616585988 hasConcept C2778048844 @default.
• W2616585988 hasConcept C2778118209 @default.
• W2616585988 hasConcept C2778371730 @default.
• W2616585988 hasConcept C2779357621 @default.
• W2616585988 hasConcept C33923547 @default.
• W2616585988 hasConcept C45355965 @default.
• W2616585988 hasConcept C50522688 @default.
• W2616585988 hasConcept C71924100 @default.
• W2616585988 hasConceptScore W2616585988C110121322 @default.
• W2616585988 hasConceptScore W2616585988C121426985 @default.
• W2616585988 hasConceptScore W2616585988C134306372 @default.
• W2616585988 hasConceptScore W2616585988C136264566 @default.
• W2616585988 hasConceptScore W2616585988C144133560 @default.
• W2616585988 hasConceptScore W2616585988C147859227 @default.
• W2616585988 hasConceptScore W2616585988C162324750 @default.
• W2616585988 hasConceptScore W2616585988C203014093 @default.
• W2616585988 hasConceptScore W2616585988C2776120307 @default.
• W2616585988 hasConceptScore W2616585988C2778048844 @default.
• W2616585988 hasConceptScore W2616585988C2778118209 @default.
• W2616585988 hasConceptScore W2616585988C2778371730 @default.
• W2616585988 hasConceptScore W2616585988C2779357621 @default.
• W2616585988 hasConceptScore W2616585988C33923547 @default.
• W2616585988 hasConceptScore W2616585988C45355965 @default.
• W2616585988 hasConceptScore W2616585988C50522688 @default.
• W2616585988 hasConceptScore W2616585988C71924100 @default.
• W2616585988 hasFunder F4320306137 @default.
• W2616585988 hasIssue "1" @default.
• W2616585988 hasLocation W26165859881 @default.
• W2616585988 hasLocation W26165859882 @default.
• W2616585988 hasLocation W26165859883 @default.

• next